Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Apr 18, 2019 4:57pm

174 Views

Post# 29646981

RE:RE:RE:RE:RE:RE:RE:Primary and secondary endpoints.....

G1945V, don't ignore the obvious. Last patient study visits and/or phone interviews need to happen before database lock. Only after database lock will unblinded data be available for analysis. As stated in the news release: "Database Lock (DBL) will occur after the last patients final visit and the last query is resolved. Approximately two weeks after DBL, the primary endpoint and additional secondary and exploratory endpoints are expected to be announced." BearDownAZ

Bullboard Posts

Visionstate set to leverage success in the U.S. market